Positive results from US-veteran mental health trial
Filed with ASX · · 3 pages · English
• Clinical trial has shown that TRI’s single-lead algorithm can support early detection of cMDE, which aligns with the VA’s priorities and strengthens the Company’s commercial position The trial utilised the Company’s single-channel ECG algorithm, which is an extension of lead asset, MEB-001. The algorithm accurately performs sleep staging and detects cMDE in subjects using only heart rate (HR) an
Story so far
Earlier from TrivarX
- TRI Exercises Option to Advance Acquisition of Stabl-Im
- September 2025 Quarterly Activities Report and Appendix 4C
- US-veteran mental health trial patient recruitment complete
- Acquisition of Stabl-Im technology and Private Placement
- Reinstatement to Official Quotation
Later from TrivarX
- December 2025 Quarterly Activities Report and Appendix 4C
- Appendix 4D & Half-Year Financial Report to 31 December 2025
- Dr Danielle Meyrick appointed as CEO
- March 2026 Quarterly Activities Report and Appendix 4C
- CRO Engaged to Advance Stabl-Im Phase 1 Trial
Follow TrivarX into a list and get an email when it puts out news.
Follow TrivarX